VEGFA and asthenia: As regards most common safety events, anti-VEGF strategies increased the risk for asthenia (RR 1.34, 95% CI 1.03–1.75), with a trend for neutropenia (RR 1.17 95% CI 0.98–1.40) and vomiting (RR 1.37, 95% CI 0.94–2.00).